Chen Su

Chen Su


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in Oral Diseases
Verified
Journal Article
Open access
GHGuangzhao Huang
Guangzhao Huang
CSChen Su
Chen Su
JHJialu He
Jialu He
HLHonglin Li
Honglin Li
ZMZhongkai Ma
Zhongkai Ma
CLChunjie Li
Chunjie Li
Objective: Histone lysine lactylation (Kla) plays a vital role in cancer progression. However, the prognostic value of histone Kla in oral squamous cell carcinoma (OSCC) remains unclear.Materials and Methods: OSCC RNA expression data were obtained from the TCGA and GEO databases. We explored the prognostic value of histone Kla in OSCC via constructing a Cox model and determined the role of Kla in OSCC drug susceptibility and tumor microenvironment (TME). In addition, the biological roles of candidate biomarkers were identified.Results: A total of 1223 Kla‐specific genes were obtained, with 228 DEKlaGs in OSCC. GO and KEGG enrichment analyses suggested that DEKlaGs contributed to inflammatory and cancer progression. A Cox model in accordance with BCAM, CGNL1, DGKG, and OLR1 could predict OSCC patient prognosis accurately. Subsequently, Kla‐induced prognostic genes were identified to play a crucial role in OSCC drug therapy and TME. Moreover, BCAM was identified as a biomarker that promoted OSCC invasion, angiogenesis, and chemotherapy resistance.Conclusion: Kla was identified to be associated with OSCC prognosis, drug therapy, and TME. Histone Kla‐induced BCAM was identified to play a crucial role during OSCC progression, suggesting that Kla is promising to be a novel therapeutic target for OSCC.

2 June 2025 in Cancer Letters
Verified
Journal Article
Closed access
CSChen Su
Chen Su
GHGuangzhao Huang
Guangzhao Huang
ZGZhiyong Guo
Zhiyong Guo
ZGZijian Guo
Zijian Guo
CCChang Cao
Chang Cao
CLChunjie Li
Chunjie Li

26 February 2018 in RMD Open
Verified
Journal Article
Open access
PDF file
FBFilip Van Den Bosch
Filip Van Den Bosch
PMPhilip J Mease
Philip J Mease
JSJoachim Sieper
Joachim Sieper
DBDominique L Baeten
Dominique L Baeten
YXYinglin Xia
Yinglin Xia
ISIn-Ho Song
In-Ho Song
Objectives Describe efficacy and safety of 3 years of adalimumab treatment in patients with peripheral spondyloarthritis (pSpA) and identify predictors of remission. Methods Patients with pSpA were randomised to adalimumab 40 mg every other week or placebo for 12 weeks; a 144-week open-label extension followed (NCT01064856). Remission was assessed by the Peripheral SpA Response Criteria (PSpARC) and Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS ID). Logistic regression analyses were performed to determine predictors of remission at 1 and 3 years and sustained remission (≥24 consecutive weeks). Results In 165 patients, ASDAS ID was achieved by 47% at 1 year and 39% at 3 years; 36% and 33% achieved PSpARC remission, respectively. Sustained ASDAS ID and PSpARC remission were achieved by 52% (86/165) and 42% (70/165) of patients, respectively. Achieving ASDAS ID at week 12 significantly predicted 1 year (OR, 8.64 (95% CI 2.97 to 25.14)), 3 year (OR, 36.12 (95% CI 2.29 to 569.08)) and sustained ASDAS ID (OR, 8.01 (95% CI 2.47 to 25.97)); achieving PSpARC remission at week 12 consistently predicted 1 year (OR, 6.47 (95% CI 1.91 to 21.95)), 3 years (OR, 15.66 (95% CI 4.19 to 58.56)) and sustained PSpARC remission (OR, 20.27 (95% CI 5.37 to 76.46)). No baseline variables consistently predicted 1-year or 3-year remission or sustained remission. The safety profile of adalimumab was consistent with observations in other SpA disease indications. Conclusions In patients with pSpA, early response to adalimumab, but not baseline demographics or disease characteristics, was a better predictor of long-term remission.

1 April 2020 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
XKXin Ku
Xin Ku
CCChunlin Cai
Chunlin Cai
YXYan Xu
Yan Xu
CSChen Su
Chen Su
ZZZhenhua Zhou
Zhenhua Zhou
YWYan Wei
Yan Wei
Background: Bone metastasis is the third most common metastatic cancers worldwide. It is a group of highly heterogeneous diseases with various potential cancer primaries. Among them, one third was diagnosed as bone metastasis of unknown primary (BMUP) due to lack of indication for the primary tumor even after comprehensive examinations. Thus, the prognosis of BMUP is often very poor since the treatment was largely empirical and untargeted. To assist identification of the primary tumor, a series of molecular markers including traditional tissue-specific histochemistry as well as gene and mRNA markers were developed with moderate to good sensitivity and specificity. Methods: In this paper, we carried out a comprehensive expression profiling for fresh-frozen tissue samples of bone metastasis from lung, prostate and liver cancers using high resolution, data-independent-acquisition mass spectrometry (DIA-MS). The proteome variation was analyzed and protein classifiers were prioritized. Results: Over 6,000 proteins were quantified from 18 samples, which, to the best of our knowledge, was never achieved before. Further statistical analysis and bioinformatics data mining revealed 4 significant proteins (RFIP1, CK15, ESYT2, and MAL2) with excellent discriminating capabilities with AUCs higher than 0.8. Conclusions: The comprehensive proteome map of bone metastases will complement available genomic and transcriptomic data. Newly discovered protein classifiers will expand current diagnostic arsenal for tissue of origin studies in BMUP. Furthermore, the proteome map generated in this study by DIA-MS allows future data re-mining as our knowledge advances to assist investigation of bone metastasis and progression of tumors as well as the development of diagnostic tools and prognosis management for BMUPs.

1 January 2015
Verified
Book Chapter
Closed access
PDF file
CSChen Su
Chen Su
DDDeguang Duan
Deguang Duan
FNFu Niu
Fu Niu
XRXudong Ren
Xudong Ren
XZXiuguo Zhao
Xiuguo Zhao